research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research At The Crossroads Of Two Alopecias: Androgenetic Alopecia Pattern Of Hair Regrowth In Patients With Alopecia Areata Treated With Oral Janus Kinase Inhibitors
JAK inhibitors help hair regrowth but not fully effective for androgenetic alopecia.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Janus Kinase Inhibitors for the Use of Alopecia Areata: A Promising Therapeutic of the Future
JAK inhibitors show promise as a future treatment for hair loss.
research Treatment of Severe Alopecia Areata with the Oral Janus Kinase Inhibitor, Tofacitinib: A Retrospective Chart Review
Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
research Janus Kinase (JAK) Inhibitors in Treating Alopecia Areata (AA)
JAK inhibitors may help treat alopecia areata and promote hair regrowth.
research Treatment of Lichen Planopilaris With Janus Kinase Inhibitors
Janus kinase inhibitors may help treat lichen planopilaris.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Efficacy and Adverse Effects of Oral Janus Kinase Inhibitor Use in Patients With Lichen Planopilaris: A Retrospective Case Series and Systematic Review
Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
research Patient Experience of Off-Label Janus Kinase Inhibitor Use for Alopecia Areata in a Cohort of 34 Patients From a Single UK Practitioner: Exploring Changing Trends in Healthcare Provision and Access to Drug Treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research Janus Kinase Inhibitor Increases Hair Growth by Increasing Beta-Catenin Activity in Outer Root Sheath Cells
JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Use of Intramuscular Triamcinolone Acetonide in Intermediate Responders to Janus Kinase Inhibition for Alopecia Areata: Case Report
IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
research In-Silico Screening of ATP-Competitive Inhibitory Activities of Phytochemicals Against Janus Kinase 3 and Its In-Vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Are Janus Kinase (JAK) Inhibitors Beneficial in the Treatment of Androgenic Alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research The Janus Kinase 1 Inhibitor Abrocitinib for the Treatment of Oral Lichen Planus
research Oral Janus Kinase Inhibitors for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Inhibiting Janus Kinases to Treat Alopecia Areata
JAK inhibitors might help treat alopecia areata.
research Response to Effectiveness of Dutasteride in a Large Series of Patients with Frontal Fibrosing Alopecia in Real Clinical Practice
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
research 63-Year-Old Female with Diffuse Thinning of the Hair
Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.
research Observation and Consideration on Using of JAKi in Clinical Trials in Times of COVID-19
Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.